A generic drug lobbying group reached an agreement with Connecticut that would halt litigation over a state drug pricing law, making the latest turn in a slew of battles over states’ attempts to rein in pharmaceutical prices.
Filed Monday with the US District Court for the District of Connecticut, the proposed agreement would cap off the Association for Accessible Medicines’ legal challenge against Connecticut over a law meant to prohibit excessive price increases on generic drugs.
AAM in its lawsuit alleged Connecticut’s law, set to go into effect in January, illegally regulated interstate sales between drug manufacturers and wholesales.
The ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
